Dynavax Technologies CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Dynavax Technologies Corporation is strongly urging its stockholders to vote for its four director nominees at the upcoming June 11, 2025 Annual Meeting, emphasizing the company's successful strategic repositioning and significant long-term stockholder value creation.
DEFA14A: Dynavax Rejects Glass Lewis Recommendations, Defends Board and Strategy Ahead of Annual Meeting
Dynavax Technologies Corporation issued a statement on June 5, 2025, disagreeing with Glass Lewis's recommendations against two board members, asserting its successful vaccine-focused strategy and strong financial position.
Dynavax Technologies Corporation is urging its stockholders, including employees, to vote using the company's 'GOLD' proxy card for the upcoming June 11 Annual Meeting, highlighting support from two independent proxy advisory firms amidst a contested proxy.
Dynavax Technologies Corporation strongly disagrees with Glass Lewis's partial recommendation against its director nominees, asserting its current strategy and board are delivering significant long-term stockholder value and urging votes for all four of its highly qualified directors.
DEFA14A: Dynavax Secures Key ISS Endorsement Ahead of Annual Meeting, Reaffirming Current Strategy and Board
Leading independent proxy advisory firm ISS has recommended Dynavax stockholders vote FOR all four of the company's director nominees, signaling support for the current strategy and leadership against an activist campaign.
Dynavax is urging stockholders to vote for its four director nominees to protect the company's positive trajectory and long-term value against Deep Track's proposed changes.
DEFA14A: Dynavax Defends Strategy Against Deep Track, Highlights Stockholder Value and Pipeline Potential
Dynavax Technologies Corporation is urging stockholders to vote for its board nominees, highlighting its successful transformation into a commercial-stage vaccine company and defending its strategy against a challenge from Deep Track Capital.
Dynavax urges stockholders to vote for its director nominees, highlighting strong financial results and shareholder returns, while criticizing Deep Track's proposed strategy as value-destructive.
Dynavax Technologies responds to Deep Track Capital's investor presentation, emphasizing its record financial results, continued momentum, and strategic plan for long-term value creation.
Dynavax issues a statement and mails a letter to stockholders, emphasizing record financial results and continued momentum, while criticizing Deep Track's investor presentation as misleading and focused on short-term gains at the expense of long-term value.
Dynavax Technologies Corporation is urging its stockholders to use the gold proxy card to vote for the company's director nominees and proposals at the upcoming 2025 Annual Meeting of Stockholders.
Dynavax is urging stockholders to vote for its four director nominees at the upcoming Annual Meeting, highlighting the Board's role in overseeing significant value creation and dismissing a challenge from Deep Track Capital.
Deep Track Biotechnology Master Fund is soliciting proxies to elect four director nominees to the Dynavax Technologies Corporation board, citing concerns over the company's capital allocation strategy and board entrenchment.
DEFA14A: Dynavax Urges Stockholders to Vote for Director Nominees Amid Proxy Contest with Deep Track Capital
Dynavax is urging stockholders to vote for its director nominees at the upcoming Annual Meeting on June 11, 2025, highlighting the company's strong financial performance and strategic direction, while criticizing Deep Track Capital's proposed changes.
Dynavax Technologies is urging stockholders to vote for its board nominees and against a stockholder proposal from Deep Track Capital at the upcoming annual meeting.
Dynavax files preliminary proxy statement amid a contested director election at the 2025 Annual Meeting, highlighting a disagreement with Deep Track over the company's strategic direction.
Dynavax addresses Deep Track Capital's nomination of board candidates, emphasizing its strong financial performance and commitment to long-term stockholder value.
Dynavax Technologies Corporation issued a supplement to its proxy statement to reflect the appointment of Ryan Spencer to the Board of Directors of Cidara Therapeutics, Inc.
Dynavax Technologies Corporation has filed a definitive proxy statement with the SEC.
Dynavax Technologies is holding its 2024 Annual Meeting of Stockholders virtually on May 23, 2024, to vote on key proposals including director elections, an equity incentive plan amendment, executive compensation, and auditor ratification.